Federal compounding law, policy and litigation
- Section 503A: https://uscode.house.gov/us/usc/119-120/t21/s353a/
- Section 503B: https://uscode.house.gov/us/usc/119-136/t21/s353b/
- FDA GLP-1 compounding policy and historical deadlines: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Tirzepatide determination: https://www.fda.gov/media/184606/download?attachment=
- Semaglutide determination: https://www.fda.gov/media/185526/download?attachment=
- Fifth Circuit, tirzepatide: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
- Fifth Circuit, semaglutide: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- FDA 503A prescription guidance: https://www.fda.gov/media/97347/download
- FDA 503A copy guidance: https://www.fda.gov/media/98973/download
- Empower warning letter, September 18, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- FDA proposed 503B exclusion announcement: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- Proposed 503B exclusion notice: https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- HHS peptide policy: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- HHS October 30 notice: https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
Quality, state standards and traceability
- FDA outsourcing-registration explanation: https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- FDA FY2027 registration information: https://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees
- FDA multidose-vial letter, hosted by Arizona Board of Nursing: https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
- Import Alert 66-80: https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
- FDA concerns about unapproved GLP-1 products: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- California approved regulations: https://www.pharmacy.ca.gov/laws_regs/approved_regs.shtml
- California Board FAQs: https://pharmacy.ca.gov/online/faqs.shtml
- California Senate Appropriations results, August 13, 2026: https://sapro.senate.ca.gov/system/files/2026-08/hearing_results-8-13-26-suspense.pdf
- USP <797> FAQ: https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0
- HHS cross-state licensing: https://telehealth.hhs.gov/licensure/licensing-across-state-lines
- FDA DSCSA exemption letter: https://www.fda.gov/media/194424/download
- FDA DSCSA exemption page: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- DSCSA statutory text: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act
- Pure Indulgence Aesthetics warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
Approvals, coverage, safety and telehealth enforcement
- Wegovy tablet approval package: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf
- Foundayo approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- CMS April 21 Bridge/BALANCE update: https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf
- CMS Bridge launch: https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
- CMS Bridge prescriber instructions: https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
- CMS Bridge Part D FAQ: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- CMS BALANCE model: https://www.cms.gov/priorities/innovation/innovation-models/balance
- FDA November 9 NAION communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- FDA January 13 suicidal-behaviour/ideation communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
- FDA March 3 telehealth warning-letter announcement: https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- FTC November 10 case entry: https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers-health-inc-ftc-v-timeline-item-2026-11-10
- FTC amended-complaint announcement: https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices
Sources cited on this page
- uscode.house.gov · Source 1 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/
- uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 4 ↗https://www.fda.gov/media/184606/download?attachment=
- fda.gov · Source 5 ↗https://www.fda.gov/media/185526/download?attachment=
- ca5.uscourts.gov · Source 6 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
- ca5.uscourts.gov · Source 7 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- fda.gov · Source 8 ↗https://www.fda.gov/media/97347/download
- fda.gov · Source 9 ↗https://www.fda.gov/media/98973/download
- fda.gov · Source 10 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- fda.gov · Source 11 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- federalregister.gov · Source 12 ↗https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- hhs.gov · Source 13 ↗https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
- govinfo.gov · Source 14 ↗https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
- fda.gov · Source 15 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- fda.gov · Source 16 ↗https://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees
- azbn.gov · Source 17 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
- accessdata.fda.gov · Source 18 ↗https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html
- fda.gov · Source 19 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- pharmacy.ca.gov · Source 20 ↗https://www.pharmacy.ca.gov/laws_regs/approved_regs.shtml
- pharmacy.ca.gov · Source 21 ↗https://pharmacy.ca.gov/online/faqs.shtml
- sapro.senate.ca.gov · Source 22 ↗https://sapro.senate.ca.gov/system/files/2026-08/hearing_results-8-13-26-suspense.pdf
- pages.usp.org · Source 23 ↗https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0
- telehealth.hhs.gov · Source 24 ↗https://telehealth.hhs.gov/licensure/licensing-across-state-lines
- fda.gov · Source 25 ↗https://www.fda.gov/media/194424/download
- fda.gov · Source 26 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- fda.gov · Source 27 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act
- fda.gov · Source 28 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
- accessdata.fda.gov · Source 29 ↗https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf
- fda.gov · Source 30 ↗https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- cms.gov · Source 31 ↗https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf
- cms.gov · Source 32 ↗https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
- cms.gov · Source 33 ↗https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
- cms.gov · Source 34 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- cms.gov · Source 35 ↗https://www.cms.gov/priorities/innovation/innovation-models/balance
- fda.gov · Source 36 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- fda.gov · Source 37 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
- fda.gov · Source 38 ↗https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- ftc.gov · Source 39 ↗https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers-health-inc-ftc-v-timeline-item-2026-11-10
- ftc.gov · Source 40 ↗https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices